Rapid Advances In Cancer Treatment Fell Another Clinical Program
This article was originally published in Scrip
Executive Summary
The availability of new immuno-oncology treatments and heightening competition in lung cancer therapeutic development are behind a decision by GlaxoSmithKline and Five Prime Therapeutics, Inc. to discontinue development of their fibroblast growth factor (FGF) ligand trap in squamous non-small cell lung cancer. They will, however, continue an ongoing study in mesothelioma, and Five Prime said it would seek to take back rights from GSK for the indication should promising early data be confirmed by the full results of a Phase Ib study.